{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:09:33Z","timestamp":1766178573409,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10792-021-02010-w","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T01:02:12Z","timestamp":1629766932000},"page":"167-175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of omalizumab on allergic conjunctivitis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1004-9492","authenticated-orcid":false,"given":"E.","family":"K\u0131r\u0131kkaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"De\u011firmenci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"2010_CR1","unstructured":"Summary of Product Characteristics Xolair\u00ae. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPARProduct_Information\/human\/000606\/WC500057298.pdf"},{"key":"2010_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jaip.2014.03.010","volume":"2","author":"M Humbert","year":"2014","unstructured":"Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, Holgate S (2014) Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2:525\u2013536","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2010_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","volume":"154","author":"NA Hanania","year":"2011","unstructured":"Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Riviera I, Zu J, Rosen KE, Eisner MD, Wong DA, Busse W (2011) Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 154:573\u2013582","journal-title":"Ann Intern Med"},{"key":"2010_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1710-1492-9-47","volume":"9","author":"G-J Braunstahl","year":"2013","unstructured":"Braunstahl G-J, Chlumsk\u00fd J, Peachey G, Chen C-W (2013) Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy Asthma Clin Immunol 9:47","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2010_CR5","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1183\/09031936.00008115","volume":"46","author":"A Deschildre","year":"2015","unstructured":"Deschildre A, Marguet C, Langlois C, Pin I, Rittie J-L, Derelle J, Taam RA, Fayon M, Brouard J, Dubus JC et al (2015) Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J 46:856\u2013859","journal-title":"Eur Respir J"},{"key":"2010_CR6","unstructured":"Food and Drug Administration. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/103976s5211lbl.pdf"},{"key":"2010_CR7","unstructured":"European Medicines Agency. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines(human\/medicines\/000606\/human_med_001162.jsp&mid=WC0b01ac058001d124"},{"issue":"2","key":"2010_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/ACI.0000000000000044","volume":"14","author":"CE Baena-Cagnani","year":"2014","unstructured":"Baena-Cagnani CE, Gomez RM (2014) Current status of therapy with omalizumab in children. Curr Opin Allergy Clin Immunol 14(2):149\u2013154","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"8","key":"2010_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2147\/DDDT.S49409","volume":"7","author":"C Incorvaia","year":"2014","unstructured":"Incorvaia C, Mauro M, Russello M, Formigoni C, Riario-Sforza GG, Ridolo E (2014) Omalizumab, an anti immunoglobulin E antibody: state of the art. Drug Des Dev Ther 7(8):197\u2013207","journal-title":"Drug Des Dev Ther"},{"key":"2010_CR10","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1111\/all.13178","volume":"72","author":"A Leonardi","year":"2017","unstructured":"Leonardi A, Doan S, Fauquert JL, Bozkurt B, Allegri P, Marmouz F, Rondon C, Jedrjezczak M, Hellings P, Delgado L et al (2017) Diagnostic tools in ocular allergy. Allergy 72:1485\u20131498","journal-title":"Allergy"},{"key":"2010_CR11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.29262\/ram.v61i3.38","volume":"61","author":"G Cortes-Morales","year":"2014","unstructured":"Cortes-Morales G, Velasco-Medina AA, Arroyo-Cruz ME, Velazquez- SG (2014) Frequency of sensitization to aeroallergens in patients with seasonal and perennial allergic conjunctivitis. Rev Alerg Mex 61:141\u2013146","journal-title":"Rev Alerg Mex"},{"key":"2010_CR12","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/cea.12536","volume":"45","author":"A Leonardi","year":"2015","unstructured":"Leonardi A, Piliego F, Castegnaro A, Lazzarini D, La Gloria VA, Mattana P, Fragona I (2015) Allergic conjunctivitis: a cross-sectional study. Clin Exp Allergy 45:1118\u20131125","journal-title":"Clin Exp Allergy"},{"key":"2010_CR13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/ACI.0000000000000204","volume":"15","author":"A Leonardi","year":"2015","unstructured":"Leonardi A, Castegnaro A, Valerio AL, Lazzarini D (2015) Epidemiology of allergic conjunctivitis: clinical appearance and treatment patterns in a population-based study. Curr Opin Allergy Clin Immunol 15:482\u2013488","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"2010_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jaci.2004.10.042","volume":"115","author":"SJ Ono","year":"2005","unstructured":"Ono SJ, Abelson MB (2005) Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 115(1):118\u2013122","journal-title":"J Allergy Clin Immunol"},{"key":"2010_CR15","first-page":"1","volume":"3","author":"S Walker","year":"2005","unstructured":"Walker S, Monteil M, Phelon K, Lasserson TJ, Hadyn WE (2005) Anti-IgE for chronic asthma in adults and children. Cochrane Libr 3:1\u201361","journal-title":"Cochrane Libr"},{"key":"2010_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2332\/allergolint.55.379","volume":"55","author":"K Okubo","year":"2006","unstructured":"Okubo K, Ogino S, Nagakura T, Ishikawa T (2006) Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int 55:379\u2013386","journal-title":"Allergol Int"},{"key":"2010_CR17","first-page":"305","volume":"17","author":"TA Klerk","year":"2013","unstructured":"Klerk TA, Sharma V, Arkwright PD, Biswas S (2013) Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. JAAPOS 17:305\u2013306","journal-title":"JAAPOS"},{"issue":"4","key":"2010_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaophthalmol.2015.5679","volume":"134","author":"E Heffler","year":"2016","unstructured":"Heffler E, Picardi G, Liuzzo MT, Pistorio MP, Crimi N (2016) Omalizumab treatment of vernal keratoconjunctivitis. JAMA Ophthalmol 134(4):461\u2013463","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"2010_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/pai.12737","volume":"28","author":"F Occasi","year":"2017","unstructured":"Occasi F, Duse M, Nebbioso M, Castro G, Fralia M, Capata G, Lollobrigida V, Zicari AM (2017) Vernal keratoconjunctivitis treated with omalizumab: a case series. Pediatr Allergy Immunol 28(5):503\u2013505. https:\/\/doi.org\/10.1111\/pai.12737","journal-title":"Pediatr Allergy Immunol"},{"key":"2010_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.04.2010.2919","author":"C Taille","year":"2010","unstructured":"Taille C, Doan S, Neukirch C, Aubier M (2010) Omalizumab for severe atopic keratoconjunctivitis. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr.04.2010.2919","journal-title":"BMJ Case Rep"},{"key":"2010_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000199719","volume":"149","author":"S Ogino","year":"2009","unstructured":"Ogino S, Nagakura T, Okubo K, Sato N, Takahashi M, Ishikawa T (2009) Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated. Int Arch Allergy Immunol 149:239\u2013245","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"2010_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1089\/jop.2004.20.533","volume":"20","author":"SS Samudre","year":"2004","unstructured":"Samudre SS, Lattanzio FJR, Williams PB, Sheppard JDJR (2004) Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther 20(6):533\u2013547","journal-title":"J Ocul Pharmacol Ther"},{"key":"2010_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/01.ico.0000127481.23714.b6","volume":"24","author":"EG Romanowski","year":"2005","unstructured":"Romanowski EG, Pless P, Yates KA, Gordon YJ (2005) Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes viral shedding in experimental adenovirus models. Cornea 24:86\u201391","journal-title":"Cornea"},{"issue":"3","key":"2010_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0002-9394(02)01982-7","volume":"135","author":"SM Rikkers","year":"2003","unstructured":"Rikkers SM, Holland GN, Drayton GE, Michel FK, Torres MF, Takahashi S (2003) Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 135(3):297\u2013302","journal-title":"Am J Ophthalmol"},{"key":"2010_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/01.ico.0000151507.49565.6e","volume":"24","author":"MA Joseph","year":"2005","unstructured":"Joseph MA, Kaufman HE, Insler M (2005) Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea 24:417\u2013420","journal-title":"Cornea"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02010-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-021-02010-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02010-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T19:30:09Z","timestamp":1699385409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-021-02010-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2010"],"URL":"https:\/\/doi.org\/10.1007\/s10792-021-02010-w","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"type":"print","value":"0165-5701"},{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"assertion":[{"value":"20 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Confirmation was received from the Ethical Board of the local committee, written informed consent was provided from all the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics confirmation and consent to participate"}},{"value":"We permit for broadcasting.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission for publication"}}]}}